

Imugene to present at the RedChip Global Online Microcap Conference

Melbourne, Australia, 10 February 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, announces that it is scheduled to present at the RedChip Global Online Microcap Conference on Thursday, February 11, 2016, at 4:30 PM ET in the US, which is Friday, February 12, 2016 at 8:30 AM AEDT in Melbourne. The presentation can be viewed at www.redchip.com. A live Q&A session will follow the investor presentation.

The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change. For the Conference schedule visit www.redchip.com/events/4/february-2016-global-online-growth-conference#schedule.

The Imugene webcast will be available at www.redchip.com/company/biotech/IMU.AX/293/imu.

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

For further information, please visit www.imugene.com.

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit www.facebook.com/imugene.

About RedChip

RedChip is a world leader in investor relations, financial media, and research for microcap, small-cap, and mid-cap stocks. Founded in 1992, and headquartered in Orlando, Florida, with affiliates in New York, Pittsburgh, Paris, and Seoul, RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the US. RedChip's unique platform combines traditional investor relations services with multi-media marketing, and its targeted retail and institutional digital media platform reaches hundreds of thousands of investors worldwide through quarterly Global Online CEO Conferences, a weekly small-cap newsletter, social media, and more. RedChip's robust platform includes a weekly television show, "The RedChip Money Report," which reaches more than 160 million households in Australia, Europe, Asia, and Latin America (<http://www.redchip.com/tv>).

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer
Tel: +61 458 040 433 (Australia), [leslie.chong \[at\]imugene.com](mailto:leslie.chong@imugene.com)

Paul Hopper, Executive Chairman
Tel: +61 406 671 515 (Australia), [receptogen\[at\]earthlink.net](mailto:receptogen@earthlink.net)

Stuart Roberts, Head of Corporate Development
Tel: +61 447 247 909, [sroberts \[at\]imugene.com](mailto:sroberts@imugene.com)

Media:

Rudi Michelson, Monsoon Communications
Tel: +61 3 9620 3333, [rudim\[at\]monsoon.com.au](mailto:rudim@monsoon.com.au)